EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects

Paul Miller, Daniel Repplinger, Rui Zhu, Yiling Chen, Nicholas Lewin-Koh, David Morris, Paul Russell, Gaohong She, Nand Singh, Rachael White, Denisa Wilkes, Hubert Chen und 1 weitere

Therapeutic Advances in Respiratory Disease · 2025

DOI: 10.1177/17534666251393346 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Paul Miller und 12 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Chloride Channel Agonists, Lung. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Enterprise Therapeutics Limited, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease, and non-CF bronchiectasis are significant global health burdens. Current treatments aim to improve mucus clearance but do not fully address these diseases, highlighting the need for novel treatments. This study presents the results from phase I and phase IIb trials of GDC-6988, an inhaled, selective, and potent TMEM16A potentiator, in healthy volunteers.

Objectives

To assess the safety and tolerability of orally inhaled GDC-6988 (nebulized and as a dry powder inhaler) in healthy subjects compared with placebo.

Design

The phase I trial was a first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and repeat doses of nebulized GDC-6988.

Methods

The study consisted of three parts: Part A with six cohorts (doses from 1.5 mg to 150 mg) using a single ascending dose (SAD) design; Part B with three cohorts (22.5 mg BID for 7 days, 75 mg BID for 14 days, and 45 mg BID for 14 days) using a multiple ascending dose (MAD) design; and Part C assessing the effect of salbutamol pretreatment on the highest dose tested in Part B (75 mg). The phase Ib study was a double-blind, randomized, placebo-controlled, single-center, multiple-dose escalation study evaluating the safety and PK of GDC-6988 DPI formulation, with and without salbutamol pretreatment. Three cohorts with doses of 11.2 mg, 28 mg, and 42 mg BID were tested. A bridging cohort compared PK in two capsule strengths of GDC-6988.

Results

In the phase I study, 76 healthy subjects received GDC-6988 or placebo; in the phase Ib study, 41 subjects were enrolled (31 in MAD cohorts, 10 in the bridging cohort). GDC-6988 was safe and generally well tolerated, with no serious, severe, or grade ⩾3 adverse events observed at any dose level. Mild-to-moderate dose-dependent FEV 1 declines were observed in both studies, but were mitigated by salbutamol pretreatment. In both trials, plasma PK concentrations of GDC-6988 were low, as expected.

Conclusion

Inhaled GDC-6988 was safe and well tolerated across all dose levels. The plasma PK of GDC-6988 was low and generally dose-proportional with a relatively short half-life.

Trial registration

Phase I: ClinicalTrials.gov Identifier NCT04488705; Phase Ib: ISRCTN30841680.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chloride Channel AgonistsLungHumansDouble-Blind MethodMaleAdultFemaleAdministration, InhalationYoung AdultHealthy VolunteersMiddle AgedDry Powder InhalersDose-Response Relationship, DrugAdolescentBenzamidesCarbamates

Stichwörter der Autor:innen

COPDTMEM16Acystic fibrosis, GDC-6988healthy volunteersnon-CF bronchiectasisphase 1

Substanzen

Chloride Channel AgonistsrevefenacinBenzamidesCarbamates

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, CA, USA.
  • University of California San Francisco, San Francisco, CA, USA.
  • Enterprise Therapeutics, Brighton, UK.
  • Quotient Sciences, Nottingham, UK.
  • PharmaKinetic Ltd., Loughborough, England, UK.
  • Hammersmith Medicines Research Ltd, London, UK.

ORCID-Profile: Joshua Galanter

Förderung

  • Enterprise Therapeutics Limited
  • Genentech

Zitieren

APA

Miller, P., Repplinger, D., Zhu, R., Chen, Y., Lewin-Koh, N., Morris, D., Russell, P., She, G., Singh, N., White, R., Wilkes, D., Chen, H., & Galanter, J. (2025). Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251393346

Vancouver

Miller P, Repplinger D, Zhu R, Chen Y, Lewin-Koh N, Morris D, et al. Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251393346

BibTeX
@article{Miller2025,
  author = {Miller, Paul and Repplinger, Daniel and Zhu, Rui and Chen, Yiling and Lewin-Koh, Nicholas and Morris, David and Russell, Paul and She, Gaohong and Singh, Nand and White, Rachael and Wilkes, Denisa and Chen, Hubert and Galanter, Joshua},
  title = {Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  doi = {10.1177/17534666251393346}
}
Kostenlos starten →